Abstract Excess intake of sodium, a common problem worldwide, is associated with hypertension and cardiovascular disease (CVD), and hypertension is a major risk factor for CVD. Population-wide efforts to reduce sodium intake have been identified as a promising strategy for preventing hypertension and CVD, and such initiatives are currently recommended by a variety of scientific and public health organizations. By reviewing the literature published from January 2011 to March 2013, we summarized recent economic analyses of interventions to reduce sodium intake. The evidence, derived from estimates of resultant blood pressure decreases and thus decreases in the incidence of CVD events, supports population-wide interventions for reducing sodium intake. Both lowering the salt content in manufactured foods and conducting mass media campaigns at the national level are estimated to be cost-effective in preventing CVD. Although better data on the cost of interventions are needed for rigorous economic evaluations, population-wide sodium intake reduction can be a promising approach for containing the growing health and economic burden associated with hypertension and its sequelae.
Introduction
In 2008, cardiovascular disease (CVD), the number one cause of death in the world, accounted for an estimated 17.3 million deaths, or 30 % of all deaths in that year [1] . Furthermore, CVD is projected to remain the leading cause of death worldwide in the next several decades [2] . All told, low-and middle-income countries experienced over 80 % of all CVD deaths in 2008 [1] , and the economic burden of CVD in developed countries continues to be staggering. Indeed, the annual cost of CVD in the USA was conservatively estimated for 2009 at $312.6 billion [3] . In the European Union, an analysis found that CVD cost €169 billion in 2003, with 62 % of this cost for health care, 21 % for loss of productivity, and 17 % for informal care [4] . In the UK alone, CVD cost £29.1 billion (about $53.0 billion) in 2004, 29 % of which was for coronary heart disease and 27 % of which was for cerebrovascular disease [5] . Globally, an extremely important risk factor for CVD is hypertension, and suboptimal blood pressure [systolic blood pressure (SBP) of 115 mmHg or greater] has been estimated to be responsible for an estimated 62 % of strokes and 49 % of coronary heart diseases worldwide [6] . The economic burden of hypertension ranged from 5 to 15 % of the gross domestic product in developed countries and from 2.5 to 8.0 % of the gross domestic product in developing countries [7] . These alarming statistics, combined with an ageing population and the growth in major risk factors such as obesity and physical inactivity, have caught the attention of global leaders, and in 2011 the United Nations called for the setting of a new international agenda on noncommunicable diseases, such as heart disease and stroke, and a focus on major risk factors such as high intake of salt and the use of tobacco [8] .
Reducing sodium intake has repeatedly been documented as being effective in lowering the risk of CVD and hypertension [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] , although some literature still questions the validity of universal reduction of sodium intake [23•, 24] . In fact, initiatives promoting a reduction in sodium intake began as early as the 1970s, and there are success stories in Finland and the UK [18, 25, 26] . In the USA, efforts to reduce sodium intake started as early as 1969, when at the White House Conference on Food, Nutrition, and Health, excess sodium intake was linked to hypertension [27] , and since the 1980s, advice has been consistent that the public should reduce salt intake [18] . Recently, actions in North America have accelerated. In April 2010, the Institute of Medicine released a report on strategies to reduce sodium intake in the USA [28] , and in May 2013 it released a report on sodium intake in the population [24] ; in Canada, in 2010, the federal and provincial governments agreed to an interim target of 5.75 g of salt per person per day by 2016 [29] . Similarly, in developing countries, sodium intake reduction has been on the public health priority agenda. In February 2010, the Pan American Health Organization−World Health Organization regional expert group on preventing CVD through the reduction of dietary salt outlined its recommendations for a population-based approach. In September 2011, South Africa set a target to reduce salt intake to less than 5 g per person per day (approximately 2000 mg sodium per person per day) by 2020 through a public health campaign and by regulating the food industry [14] . Irrespective of the initiatives already under way, economic analysis can help inform selection of intervention strategies for reducing salt intake. This summary of the current status of economic evaluation of sodium intake reduction to prevent CVD can be helpful in informing current initiatives, and revising current interventions or developing new ones to improve costeffectiveness. Appropriately designed interventions to reduce sodium intake should improve public health by reducing the growing burden of hypertension and CVD worldwide.
Major Types of Economic Evaluations of Preventing CVD by Reducing Sodium Intake
The presence of a public health problem is not sufficient justification for public intervention. First, the societal costs of the intervention should be less than its expected societal benefits. Second, because resources are limited, even if the costs are lower than the benefits, there is still often a need to compare these costs and benefits with those of other interventions to judge whether the possible investment in the intervention being considered is the best use of resources [30] [31] [32] . Accordingly, not all potentially beneficial interventions can be funded and/or implemented, i.e., choices must be made in allocating scarce resources. Figure 1 depicts the linkages between the five major types of economic evaluation and the impact of interventions to reduce sodium intake for the purpose of preventing CVD.
For any kind of intervention, the most basic economic evaluation is a cost analysis, although researchers often start with a cost-of-illness study. As the evaluation of interventions become more detailed, however, the need to consider the cost of the intervention will become more apparent. In fact, cost analysis is an important component of all economic evaluations and often serves as the foundation for all other kinds of economic evaluations [33] .
The three other types of economic evaluation shown in Fig. 1 link the costs (either of the intervention or of the illness, or both) with health outcomes from interventions. Because health outcomes are often measured by the number of diseases or deaths averted (CVDs averted in Fig. 1 ), one natural way of linking the costs of intervention with the health outcomes is the cost per case averted or per death avoided. This is done in a typical cost-effectiveness analysis, and it is often measured by a cost-effectiveness ratio derived by dividing the costs of the intervention by the incremental health outcomes associated with that intervention. Another type of analysis, called cost-utility analysis, links the cost of intervention to the number of life years gained from the intervention. Here, the number of life years gained is often measured by quality-adjusted life years (QALYs) or disability-adjusted life years (DALYs) to produce standardized measures. The validity of both QALYs and DALYs is debatable, however, and their use in economic evaluations should be approached with caution [34] .
If the number of cases of the disease in question or the number of deaths averted can be measured or converted to monetary terms, the linkage between the costs of the intervention and health outcomes can be expressed as a costbenefit analysis. The cost-benefit ratio is derived by dividing the costs of the intervention by the incremental monetized health outcomes. Alternatively, researchers can look at the net benefit, which simply is the difference between the total benefits from the intervention and its costs. In the costbenefit analysis, because there are no natural prices for health and human life, artificial prices must be created by methods such as willingness to pay. More often than not, however, valuing human life and health in monetary terms is a challenging issue for researchers as well as the public [35] .
and "economic aspects of illness," we searched six databases and found 91 potentially relevant articles published in English during the period from January 2011 to March 2013: PubMed, n=24; ABI Inform, n=17; EconLit, n=10; CINAHL, n=21; Embase, n=10; and WOS, n=9. After screening them to remove obviously irrelevant articles, reviews, commentary, duplicates, and articles not related to CVD, we identified five original research articles for the present review. In addition, we identified a publication of apparent relevance that was written in Spanish but had an English abstract. With that abstract and a Google translation (Google, Mountain View, CA, USA) of the text and tables, we were able to obtain 
No studies used cost-benefit analysis
Check mark this type of economic evaluation was included in the study, X the main type of economic evaluation in the study sufficient economic information and thus included it in our review. In all, the six publications came from six different countries: the USA [36••] , the UK [37] , Finland [38] , Vietnam [39] , Australia [40••] , and Argentina [41] . Although all but two were cost-effectiveness studies (one was a cost-of-illness study and one was a cost-utility analysis), they all included at least two types of economic evaluation (Table 1 ). The findings of the studies are summarized in Table 2 . The Selected Studies USA A study [36••] conducted in the county of Los Angeles, California, estimated the impact on blood pressure and health care costs of a local policy to reduce sodium intake. The intervention was a food-procurement policy implemented by the county to reduce the intake of sodium in various settings. The study proposed two policy scenarios to reduce the sodium content of foods: (1) reducing the sodium content of all foods in the settings of child care, senior meal programs, cafeterias, and mobile trucks; and (2) reducing sodium content by labeling foods and by promoting, subsidizing, and providing lowsodium food options in hospitals and in county government cafeterias. Using health impact assessment methods and considering the best available empirical evidence as well as the opinions, experience, and expectations of those who would be affected by the proposed policy, the authors found that if the sodium-reduction strategies were implemented, adults in the county would reduce their intake of sodium by 233 mg per day, on average, in 2010. This would correspond to an average decrease of 0.71 mmHg in SBP among adults with hypertension, 388 fewer cases of uncontrolled hypertension, and a decrease per year of $629,724 in direct health care costs. However, the study did not provide robust data on most cost components of implementing the intervention, and thus no cost-effectiveness measures were presented. Because of the variety of assumptions used and the intervention strategies postulated, the health benefits and savings in health care costs that were postulated should be considered potential at best.
UK
Using a spreadsheet model to quantify the reduction in CVD over a decade that would proceed from a population-wide risk-reduction program, the authors of this study [37] estimated the potential cost-effectiveness of such a program. Major outcomes were the number of cardiovascular events avoided, QALYs gained, and savings achieved in health care costs for a given level of effectiveness; the study also produced estimates of how much it would be worth spending to achieve a specific outcome.
The authors found that legislation or other measures to reduce the intake of salt by 3 g per person per day (in a population where the current mean intake was about 8.5 g per person per day) would reduce the mean population SBP by approximately 2.5 mmHg, prevent about 30,000 cardiovascular events and approximately 4,450 deaths, and produce discounted savings overall of approximately £347 million (about $684 million) over a decade, which would be equivalent to annual savings of approximately £40 million.
Thus, salt-reduction interventions that cost less than £40 million a year that achieved the proposed sodium intake reduction would be cost-saving. Further, any intervention that achieved even a modest population-wide reduction in the incidence of any major cardiovascular risk factor would produce a net cost saving to the National Health Service of the UK while also improving health. Unfortunately, this article did not detail the specific costs of particular programs.
Finland
In this study [38] , a Markov model with a dynamic population structure was developed to present the natural history of CVD based on the most current information on the age-and sex-specific risk factors for CVD, dietary habits, and nutrient intake of the Finnish population aged 30-74 years. The authors applied the model to predict the health economic consequences of modest reductions in the daily intake of salt and the replacement of saturated fat with polyunsaturated fat in the population of interest. For the 20 years beginning in 2007, the model predicted that this intervention could potentially prevent 8,000−13,000 CVD cases, and meanwhile added 26,000-45,000 QALYs and saved €150 million to €225 million (about $203 million to $304 million). Thus, a modest reduction in salt intake and replacing saturated fat with polyunsaturated fat in foods can significantly reduce the adult Finnish population's burden of CVD.
In this study, costs were estimated from a societal perspective and included the direct cost of prevention, morbidity, rehabilitation, and production losses due to nonfatal CVD events. Age-and sex-specific estimates of quality of life were used to represent the average quality of life in the Finnish population. The dietary reduction of 1 g of salt per day was assumed to lower SBP by approximately 1.185 mmHg among hypertensive subjects and by 0.595 mmHg among normotensive subjects. One shortcoming of the study is that it did not specify any particular intervention aimed at reducing dietary salt and intake of saturated fat; thus, the cost of specific activities was unclear.
Vietnam
This study [39] investigated the costs, health effects, and the cost-effectiveness of a group of personal and nonpersonal (i.e., at the individual and population level) strategies to reduce CVD in Vietnam. The interventions, 23 in total, included a mass media campaign that encouraged reduced consumption of salt and tobacco, the use of drugs for lowering blood pressure or cholesterol, and using combined drug therapy for people at differing absolute risk of a cardiovascular event. A health education program to reduce salt intake was the most cost-effective measure at the population level, and treating people who had SBP above 160 mmHg was the most cost-effective measure at the individual level. The authors asserted that a mass media education program on salt intake and a combination mass media program that focused on salt intake, cholesterol level, and tobacco use should be selected first. Among the 23 interventions considered, the least costly was a health education program using the mass media to reduce salt intake, with a total cost per year of 89 billion dong (equivalent to US$0.06 per person). It was also the most cost-effective, at 1.9 million dong (US$118) per DALY averted.
In this study, costs comprised program-and patient-related costs. Program costs were those incurred at the national, provincial, and district administrative levels, including training, program administration, and mass media, whereas patient costs were incurred at the point of delivery and consisted of diagnostic and laboratory tests, consultation, drugs, and hospital and health center visits. However, the very low cost of the health education program merits further investigation to ensure the validity of the data.
Australia
Using a Markov simulation model, the authors of this study [40• •] evaluated the cost-effectiveness of interventions to prevent CVD in the Australia population of men and women aged 35-84 years. The study evaluated two interventions targeting the whole population: (1) a community heart health program, and (2) mandatory reduction of salt content in the manufacture of breads, margarines, and cereals. It also examined six other interventions aimed at high-risk populations.
The authors concluded that reduction of the salt content in breads, margarines, and cereals is clearly the more effective and cost-effective strategy for the primary prevention of CVD; it produces larger improvements in the health of the population, and between the two interventions considered, it can save the most money for the health sector. The authors asserted that to achieve best value for money in the primary prevention of CVD, the Australian government must take a tougher approach in mandating limits on salt in processed foods. One drawback of the study is that although it considered or included a variety of cost items from a number of sources, it is not clear whether these data were valid inputs into the model, especially the cost of mandatory reduction of salt content. For example, the authors did not mention the costs to the government of implementing the policy or describe the costs to the manufacturers. These should have been included as intervention costs.
Argentina
This study [41] used a simulation model to measure the impact of policies on heart disease in Argentina in order to predict trends in incidence, prevalence, mortality, and cost for CVD in the population aged 35-84 years. The cost of intervention included the cost of human resources, transportation, and a mass media campaign. The authors estimated the cost-utility ratio of an intervention among people aged 35 years and older that involved reducing the salt content of foods by 5-25 %; these researchers estimated the impact and costs of a 3-g daily reduction in dietary salt intake by reducing the salt in processed food and the amount of salt that participants added to foods over a 10-year period.
In the high-impact scenario, the intervention generated a net savings of US$3.77 billion and an increase of 656,657 QALYs; in the low-impact scenario, these figures were US$2.08 billion and 401,659 QALYs. It was estimated that there would be a 24.1 % reduction in the incidence of heart disease, 21.6 % reduction in acute myocardial infarction, 20.5 % reduction in stroke, 19.9 % reduction in mortality from heart disease, and 6.4 % reduction in all-cause mortality. Benefits were observed for both genders and for all age groups. Thus, implementing this strategy to reduce salt intake would produce a very positive impact in terms of QALY gains and savings in the use of economic resources. But this study did not present the variations of the cost of interventions between high-impact and low-impact scenarios.
Summary and Conclusions
Five of the six studies that we reviewed listed the cost components of the intervention to at least some extent, but none of them used robust cost data. In the US study, which involved a local food-procurement policy to reduce sodium intake, the cost of implementation was based only on the literature as well as data gathered from interviews with 30 agency representatives and food vendors [36••] . In the study from Finland [38] , which involved a Markov model and not an actual intervention, the authors used a societal perspective to list the costs of prevention efforts, morbidity, rehabilitation, and loss of production due to nonfatal CVD events. These are not the estimated costs of an intervention to reduce salt intake, however. In the Vietnam study, for mass media campaigns (one of the options), the program costs included training, program administration, and mass media [39] . The cost estimates were based largely on expert opinion. In the Australia study [40••] , the costs of mandatory salt reduction were the costs of legislative changes and enforcement. Estimates for all these costs came from other studies or various sources. In the Argentina study, the costs of an intervention to reduce sodium intake included human resources, biochemical analysis of food, transportation, and a mass media campaign [41] . However, the study did not vary the cost when health outcome changed from low-impact to highimpact scenarios. In the UK, the authors of the study pointed out that no detailed specific costs of particular programs were available [37] .
Although five of the six studies listed cost categories for the intervention(s), all of the cost data were incomplete. This shortcoming, in turn, may have limited the robustness of the results for cost-effectiveness, thereby limiting the public health implications of these studies [42] . There might be two major reasons why the cost data were so inadequate. First, the population-wide interventions were not well defined. When the description of the intervention was not concrete or specific enough, it was hard for the authors to estimate intervention costs. Second, there might have been no economic evaluation component when the interventions were being developed or implemented. Further, all the economic evaluations were conducted after the interventions had started. Thus, at best, the authors could collect data on costs only retrospectively.
Health outcomes in the studies we reviewed were measured by the number of CVD cases or deaths averted, QALYs/DALYs gained, blood pressure reduction, and health care costs saved. Five of the six studies presented the health care costs saved. This is useful information for advocacy purposes, but is not necessary for demonstrating cost-effectiveness. Support for the study conclusions would have been stronger with more robust data on health care costs. In addition, the saving in health care costs is only a proportion of the total cost saving, as indirect costs such as productivity loss and the cost of informal care are often very large when CVD is the primary problem [4, 43] . Although the Finnish study [38] listed the costs of rehabilitation and lost productivity, it appears that the authors confused health care costs with the costs of intervention.
Except for the US study, which was a county level investigation, all other studies claimed a significant health and economic benefit through population-wide sodium intake reduction. It is interesting that although the body of literature was small, the six studies we analyzed in detail included both developed and developing countries and involved the geographic regions of North America, South America, Europe, Australia, and Asia. This suggests that population-wide efforts to reduce sodium intake are of interest globally. This is important because both hypertension and CVD affect all populations around the world. Furthermore, all evaluations claimed the population-wide interventions to be cost-effective or costbeneficial. Because the body of literature was small and only one study was conducted in each country, we cannot derive an overall comparative measure of cost-effectiveness across countries. Conducting cost-effectiveness analysis using multicountry-level data might be necessary.
Although the results of cost-effectiveness analyses are helpful to decision makers in prioritizing public health interventions [44•] , valid cost-effectiveness evaluations must be based on robust data on the cost of interventions. Without high-quality data, even the best method cannot produce useful results. Conversely, with high-quality data on costs, a cost analysis of the intervention will provide decision makers and program developers with a stronger economic argument for implementing or not implementing interventions [45] . We also need rigorous estimates of the economic burden of CVD, kidney disease, and other health conditions closely related to hypertension, especially estimates that include their indirect costs.
In conclusion, our review of recent literature allowed us to summarize the most recent economic evidence on reduction of sodium intake as it relates to the prevention of hypertension and CVD. The evidence generally supports population-wide interventions to achieve sodium intake reduction, although in each country only a single study is available on key intervention strategies such as reducing the salt content in manufactured foods and conducting mass media campaigns. The findings reinforced the findings in the literature [42] . In the USA, all previous studies used Markov or other simulation models for their cost-effectiveness evaluation and used medical cost savings as outcomes [46] [47] [48] [49] [50] . None of these studies mentioned the costs of intervention. Although the most recent US study [36••] did not provide convincing data on the cost of the intervention, the authors expended extra efforts in obtaining some of the costs for intervention implementation from the communities. This is one good step toward developing practical intervention programs. In other developed countries, we did not find similar efforts. In developing countries, the previous literature [51, 52] used too general data and methods and treated a large geographic area as a region for cost-effectiveness evaluation. Overall, although more robust data on the costs of interventions and more empirical data on health outcomes (health outcomes presented in the literature were based on projections and simulations) are needed to conduct rigorous economic evaluations, population-wide sodium intake reduction is promising in addressing the public health burden of hypertension, atherosclerosis, and their sequelae.
